Search Results - hongyan+liu

3 Results

Sort By:

Bispecific CD44 and EpCAM aptamer inhibits ovarian cancer growth

The current state of the art Like Antibodies, small nucleotide aptamers target specific biomarkers responsible for tumor progression. But they have no-immunogenicity, higher tissue penetration, higher specificity, and higher binding affinity than antibodies. Problems with current state of art Single CD44 aptamers and single EpCAM aptamers have...

Published: 7/1/2022 | Inventor(s): Hongyan Liu

Keywords(s):

Category(s): Therapeutics

Bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer

Current State of the Art Both aptamer and RNAi therapies are promising treatments for a wide range of diseases. Anti-VEGF aptamer was approved by FDA in 2017 for treating wet (age-related) macular degradation. The only FDA approved RNAi therapy is Patisiran for treating hereditary transthyretin amyloidosis with neuropathy. Aptamer and RNAi therapies...

Published: 2/4/2021 | Inventor(s): Hongyan Liu

Keywords(s):

Category(s): Therapeutics

Targeting EGFR/HER2/HER3 with a three-in-one aptamer-siRNA chimera

Current State of the Art Treatments that target one protein or gene are effective for some cancer and infectious disease. However, clinical studies showed that many patients do not respond or develop resistance to one-target treatments. Therapies with more than one targets are needed to improve clinical efficacy and expand clinical application. Problems...

Published: 2/4/2021 | Inventor(s): Hongyan Liu

Keywords(s):

Category(s): Therapeutics